Filtered By:
Condition: Stroke
Drug: Pradaxa

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 1527 results found since Jan 2013.

Stroke thrombolysis in a patient on dabigatran in the extended time window
N Z Med J. 2022 Jan 20;136(1568):105-108.NO ABSTRACTPMID:36657080
Source: New Zealand Medical Journal - January 19, 2023 Category: General Medicine Authors: Stewart Shiu Bobae Lee Karim M Mahawish Source Type: research

Safety Signal Evaluation of a Risk of Syncope and Dizziness Not Related to Bleeding or Stroke in Direct Oral Anticoagulant-Treated Patients
Clin Ther. 2023 Jan 16:S0149-2918(22)00416-7. doi: 10.1016/j.clinthera.2022.12.010. Online ahead of print.ABSTRACTPURPOSE: In clinical studies, rivaroxaban treatment has been associated with increased incidence of syncope not related to bleeding, anemia, or stroke. The study objective was to evaluate the occurrence of dizziness and/or syncope not related to bleeding, anemia, or stroke in patients treated with direct oral anticoagulants (DOACs).METHODS: A retrospective, observational, comparative study of adult patients diagnosed with atrial fibrillation and treated with DOACs was conducted using digital retrieval of medica...
Source: Clinical Therapeutics - January 18, 2023 Category: Drugs & Pharmacology Authors: Ophir Lavon Daisy Cohen Source Type: research

Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation
The objective of this study was to compare effectiveness and safety between reduced dose DOACs and high TTR warfarin treatment (TTR  ≥ 70%) in NVAF. A Swedish anticoagulation registry was used in identifying eligible patients from July 2011 to December 2017. The study cohort consisted of 40,564 patients with newly initiated DOAC (apixaban, dabigatran, or rivaroxaban) (11,083 patients) or warfarin treatment (29,481 patients ) after exclusion of 374,135 patients due to not being warfarin or DOAC naïve, not being prescribed reduced dose, having previous mechanical heart valve (MHV), or being under 18 years old. The me...
Source: Journal of Thrombosis and Thrombolysis - January 6, 2023 Category: Hematology Source Type: research

Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
ConclusionPatients with NVAF and  ≥ 6 comorbid conditions had significantly different risks for stroke/SE and MB when comparing DOACs to DOACs, and different healthcare expenses. This study's results may be useful for evaluating the risk–benefit ratio of DOAC use in patients with NVAF and multimorbidity.
Source: Advances in Therapy - December 17, 2022 Category: Drugs & Pharmacology Source Type: research

PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study
ConclusionThe study demonstrated that the prevalence of inappropriate direct oral anticoagulant dosing according to the European Heart Rhythm Association recommendations was 24.9% in patients with atrial fibrillation. Several demographic and clinical factors were associated with the inappropriate prescription of direct oral anticoagulants.
Source: Cardiovascular Drugs and Therapy - December 17, 2022 Category: Cardiology Source Type: research

Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real ‐world analysis
ConclusionIn obese patients with congestive heart failure and atrial fibrillation or atrial flutter on DOACs, apixaban has the most favorable safety profile compared to rivaroxaban and dabigatran.
Source: Pacing and Clinical Electrophysiology : PACE - December 2, 2022 Category: Cardiology Authors: Yashasvi Chugh, Kashvi Gupta, Hanumanthu Balram Krishna, Renato Quispe Ayala, Ignacio Zepeda, Michael Grushko, Robert T Faillace Tags: ORIGINAL ARTICLE Source Type: research

Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study
CONCLUSIONS: Over 12 months after initiation, apixaban and dabigatran conferred progressive increases in event free time for stroke/SE and MB vs warfarin, whereas rivaroxaban conferred an increase in stroke/SE-free time but a loss in MB-free time vs warfarin.PMID:36456387 | DOI:10.1016/j.ejim.2022.10.021
Source: European Journal of Internal Medicine - December 1, 2022 Category: Internal Medicine Authors: Steven Deitelzweig Allison Keshishian Amiee Kang Aaron Jenkins Nipun Atreja Patricia Schuler Jenny Jiang Huseyin Yuce Xiaoxi Sun Gregory Y H Lip Source Type: research

Safety and Efficacy of Rivaroxaban, Apixaban, and Dabigatran in Obese and Morbidly Obese Patients with Heart Failure and Atrial Fibrillation: A Real ‐World Analysis
ConclusionIn obese patients with congestive heart failure and atrial fibrillation or atrial flutter on DOACs, apixaban has the most favorable safety profile compared to rivaroxaban and dabigatran.This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - November 24, 2022 Category: Cardiology Authors: Yashasvi Chugh, Kashvi Gupta, Hanumanthu Balram Krishna, Renato Quispe Ayala, Ignacio Zepeda, Michael Grushko, Robert T Faillace Tags: ORIGINAL ARTICLE Source Type: research